Reconstitution of T Cell Receptor Signaling in ZAP-70–deficient Cells by Retroviral Transduction of the ZAP-70 Gene

By Naomi Taylor,* Kevin B. Bacon,* Susan Smith,* Thomas Jahn,* Theresa A. Kadlecek, Lisa Uribe,* Donald B. Kohn,* Erwin W. Gelfand, Arthur Weiss, and Kenneth Weinberg*

From the *Division of Research Immunology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California 90027; 2DNAX Research Institute, Palo Alto, California 94304; Howard Hughes Medical Institute, Department of Medicine and of Microbiology and Immunology, University of California, San Francisco, California 94143; and 3Division of Basic Sciences and Molecular Signal Transduction Program, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Diseases, Denver, Colorado 80206

Summary

A variant of severe combined immunodeficiency syndrome (SCID) with a selective inability to produce CD8 single positive T cells and a signal transduction defect in peripheral CD4+ cells has recently been shown to be the result of mutations in the ZAP-70 gene. T cell receptor (TCR) signaling requires the association of the ZAP-70 protein tyrosine kinase with the TCR complex. Human T cell leukemia virus type I–transformed CD4+ T cell lines were established from ZAP-70–deficient patients and normal controls. ZAP-70 was expressed and appropriately phosphorylated in normal T cell lines after TCR engagement, but was not detected in T cell lines from ZAP-70–deficient patients. To determine whether signaling could be reconstituted, wild-type ZAP-70 was introduced into deficient cells with a ZAP-70 retroviral vector. High titer producer clones expressing ZAP-70 were generated in the Gibbon ape leukemia virus packaging line PG13. After transduction, ZAP-70 was detected at levels equivalent to those observed in normal cells, and was appropriately phosphorylated on tyrosine after receptor engagement. The kinase activity of ZAP-70 in the reconstituted cells was also appropriately upregulated by receptor aggregation. Moreover, normal and transduced cells, but not ZAP-70–deficient cells, were able to mobilize calcium after receptor ligation, indicating that proximal TCR signaling was reconstituted. These results indicate that this form of SCID may be corrected by gene therapy.

SCID is a heterogeneous group of genetic disorders characterized by an absence of T and B lymphocyte function. Recently, one form of autosomal recessive SCID has been shown to be caused by defects in the ZAP-70 protein tyrosine kinase (PTK; 1–3). The phenotype of ZAP-70–deficient SCID is distinctive with an absence of peripheral CD8+ T cells and normal to high levels of peripheral CD4+ T cells that cannot signal through the TCR. ZAP-70 has a relative molecular mass of 70-kD, and is expressed exclusively in thymocytes, T cells, and NK cells (4). It contains two tandemly arranged Src homology 2 (SH2) domains and a carboxy-terminal kinase domain (5).

Engagement of the TCR normally results in activation of intracellular signal transduction pathways culminating in gene expression and cellular proliferation (6). Much evidence indicates that initiation of the signal is mediated through phosphorylation of two tyrosines located within a 17–amino acid motif that is present in all conserved chains of the TCR, termed the immunoreceptor tyrosine activation motif (ITAM; 7–9). The Src family PTKs Lck and Fyn have been shown to play important roles in the tyrosine phosphorylation of these ITAMs (10–12). ZAP-70 can then associate with the phosphorylated ITAMs of the CD3-ζ and CD3-ε chains of the TCR through its SH2 domains (5, 13, 14). ZAP-70 is itself phosphorylated upon this interaction, in a process that is dependent on Src family PTKs (5, 14–16). The subsequent steps in the TCR signaling pathway that result in T cell proliferation and cytokine release are not well defined. However, the observation that there is an almost complete abrogation of TCR signal transduction in CD4+ cells in ZAP-70–deficient patients (1–3) indicates a critical role for ZAP-70 in this process.

Interestingly, there is a second member of this PTK family, termed Syk, that is structurally homologous to ZAP-70 and shares 57% sequence identity (5, 17). Syk is expressed in a wide variety of cells including B cells, mast cells, gran-
ulocytes, platelets, and thymocytes, but its level in peripheral T cells is significantly lower (<10% of the level in B cells). Additionally, although Syk is known to be important for signaling in B cells, mast cells, and granulocytes, its role in T cell signaling is not clear (18–25).

We have recently shown that high levels of endogenous Syk may partially compensate for the absence of ZAP-70 in thymocytes from a ZAP-70–deficient patient, resulting in signaling through the TCR (26). In contrast with thymocyte signaling, however, there is a lack of signaling, as assessed by protein tyrosine phosphorylation and mobilization of [Ca\(^{2+}\)], in the peripheral CD4\(^+\) T cells from this patient (26). This observation again underscores the importance of ZAP-70 in the signal transduction pathway in peripheral T cells.

In the present work, we demonstrate successful reconstitution of TCR-mediated signaling in a CD4\(^+\) peripheral T cell line from this ZAP-70–deficient patient. The cell lines have previously been shown to have defective TCR-mediated signaling analogous to that seen in primary cells from the patient (26). Cells were reconstituted by retroviral-mediated transduction with the wild-type ZAP-70 gene. After transduction of the patient's cell line, TCR signaling was normalized as measured by ZAP-70 phosphorylation, ZAP-70 in vitro kinase activity, and reconstitution of calcium mobilization.

Materials and Methods

**Cell Lines.** The patient with ZAP-70 deficiency has been reported previously (26). Briefly, HTLV-I–transformation of peripheral blood T cells from normal adult donors and the ZAP-70–deficient patient (AB) were performed as described (27). The normal and AB HTLV-I lines were maintained in RPMI 1640 with 10% FCS, IL-2 (20 U/ml; gift from Carolyn Paradise, Chiron Corp., Emeryville, CA), 2 mM l-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. The phenotype of control and ZAP-70–deficient T cell lines was similar; each expressed TCR-α/β as well as CD4. Additionally, all cell lines were IL-2–dependent. The human T leukemia cell line Jurkat was maintained in RPMI 1640 with 10% FCS.

**Construction of the G1ZAPStVNa Vector and Packaging Line.** The normal ZAP-70 cDNA (5) was excised from Bluescript KS(+) as an EcoRI fragment, blunt-end ligated with Klenow DNA polymerase, and cloned into the Smal site of the pg1XStVNa vector plasmid, a Moloney murine leukemia virus–based retroviral vector (28; Generic Therapy, Inc., Gaithersburg, MD).

To generate a high titer packaging line, the resultant pGZAPStVNa plasmid was transfected into the gp+ env 86 ecotropic packaging line using DOPAT reagent (Boehringer Mannheim, Indianapolis IN) (29). Supernatants from the ecotropic line were then used to infect PG13 amphotropic packaging cells (30), and a single clone with a titer of 4 × 10\(^5\) ml was used for transductions.

**Retroviral Transductions.** pG1ZAPStVNa supernatants were added at a 1:1 dilution to AB cells in logarithmic growth phase (10\(^5\) cells/ml) in the presence of IL-2 (20 U/ml) and 3 µg/ml protamine. Fresh viral supernatants were added every 24 h for 3 successive days. The AB cells were then diluted to ~5 × 10\(^5\) cells/ml, and 1-ml aliquots were seeded into the wells of a 24-well plate and selected in 400 µg/ml of G418 (geneticin; Gibco-BRL, Gaithersburg, MD). In three different transductions, approximately four to eight wells from each plate grew after 3–6 weeks of G418 selection. Control cells were transduced with the LN vector, which contains only the neomycin phosphotransferase gene (28).

**Immunoprecipitations and Kinase Assays.** Cells were starved overnight in RPMI 1640 with 1% FCS (in the absence of IL-2). After washing twice in HBSS, cells were resuspended at 2 × 10\(^7\) cells/ml, incubated with 100 µl of a biotinylated anti-CD3 antibody (Leu-4 mAb; Becton Dickinson & Co., Mountain View, CA) for 15 min on ice, and then cross-linked with streptavidin (30 µg/ml, Calbiochem-Novabiochem Corp., La Jolla, CA) for 2 min at 37°C. Cells were lysed in an NP-40 lysis buffer (31), and postnuclear supernatants were immunoprecipitated with a rabbit polyclonal antibody to ZAP-70, 1222 (5), followed by collection on protein A/G agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Immunoprecipitates were separated on 7.5% SDS-PAGE gels and transferred electrophoretically to Hybond membranes (Amersham, Arlington Heights, IL).

Membranes were blotted with a mixture of the 4G10 (Upstate Biotechnology Inc., Lake Placid, NY) and pY72 antiphosphotyrosine mAbs (gift from Bart Sefton, Salk Institute, La Jolla, CA) as previously described (31). Blots probed with a ZAP-70–specific mAb, 2F3.2 (14), were blocked in TBS (150 mM NaCl, 20 mM Tris, pH 7.5) containing 5% BSA and 0.1% Tween 20. Immunocomplexes were visualized using the enhanced chemiluminescence detection system (Amerham).

In vitro kinase assays were performed essentially as reported (32). Immunoprecipitates were washed in lysis buffer followed by 150 mM NaCl and 50 mM Tris HCl, pH 7.5. Precipitates were then incubated in 25 µl kinase buffer (20 mM Pipes, pH 7.0, 10 mM MnCl\(_2\), and 5 µCi [γ-\(^{32}\)P]ATP [3,000 Ci/mM]) for 10 min at 30°C, washed once, eluted by boiling in 2× SDS sample buffer, resolved on SDS-PAGE, and visualized by autoradiography.

**Measurement of Cytoplasmic Calcium Concentration.** T cell lines were starved overnight in RPMI 1640 with 10% FCS (in the absence of IL-2), and were loaded with Indo-1 (Molecular Probes, Inc., Eugene, OR) in the same medium at 20°C for 45 min. Cells were washed and resuspended at ~10\(^6\) cells/ml in HBSS containing 1% BSA. Cells were stimulated with bivalent anti-CD3 mAb followed by streptavidin at 37°C in a constantly stirred acrylic cuvette. Fluorescence measurements to determine [Ca\(^{2+}\)]\(_i\) were performed with a spectrofluorometer (Photon Technologies, South Brunswick, NJ) at an excitation wavelength of 390 nm (4-nm bandwidth), and with dual simultaneous monitoring of emission at 405 and 485 nm (10-nm bandwidth). The ratio of emission at 405/485 nm was measured at a rate of 2 Hz and is presented as a function of time (s).

**Results**

**Lack of ZAP-70 Expression in a Peripheral CD4\(^+\) Cell Line Derived from Patient AB.** We have previously shown that patient AB, the product of a consanguineous union, has ZAP-70–deficient SCID (26). This syndrome was diagnosed from the patient's peripheral blood T cell phenotype (adequate CD4\(^+\) cell count with a marked paucity of CD8\(^+\) T cells), the failure of his PBMCs to mediate increases in [Ca\(^{2+}\)]\(_i\), and an absence of detectable ZAP-70 protein. Additionally, no ZAP-70–specific RNA could be detected in thymocytes from patient AB. To study signaling in peripheral CD4\(^+\) cells from this patient, an HTLV-I–transformed amphotropic packaging cell line was derived. HTLV-I–transformed CD4\(^+\) T cell lines from normal individuals were used as controls. Like CD4\(^+\) HTLV-I lines derived from normal individuals, the patient's HTLV-I T cell line expressed CD4, the Lck and Fyn Src family PTKs, the TCR-ζ chain, and PLC-γ1 (data not shown). All HTLV-I
lines required the presence of exogenous IL-2 (20 U/ml) in the culture medium to sustain growth. In contrast with control HTLV-I lines (Normal), however, ZAP-70 expression was not detected in the AB HTLV-I line (AB; see Fig. 2 B). These data indicated that the AB HTLV-I line could be used as a tool to assess whether the transduction of wild-type ZAP-70 would result in the reconstitution of TCR-mediated signaling.

ZAP-70 Is Expressed and Tyrosine Phosphorylated after Transduction with GIZAPSvNa. To determine whether wild-type ZAP-70 would restore TCR function in AB T cells, cells were transduced with a retroviral vector GIZAPSvNa, into which the entire ZAP-70 cDNA was cloned (Fig. 1). Pools of AB cells from three different transduction experiments were selected in G418 for 3-6 wk to obtain cells containing GIZAPSvNa (AB/ZAP-70 cells). In these transduced T cell pools, ZAP-70 was expressed at levels ranging from 0.2 to 2.0-fold of the levels observed in control T cell lines (data not shown). In Fig. 2 B, ZAP-70 expression in an AB/ZAP-70 T cell pool is equivalent to that observed in a normal T cell line (Normal). This indicates that retroviral transduction of ZAP-70 into deficient cells can result in approximately normal levels of ZAP-70 expression. The level of ZAP-70 expressed in six individual pools of AB/ZAP-70-transduced cells did not change after up to 8 mo of continuous culture in the absence of G418, as monitored by immunoblot analysis (data not shown). This result demonstrates that ZAP-70 can be stably expressed in cultured T cells after transduction with the GIZAPSvNa retroviral vector.

Upon TCR stimulation, ZAP-70 normally associates with phosphorylated ITAMs that are present in the CD3-ε or -γ chains, and is itself phosphorylated (5, 13–16). Therefore, we assessed whether ZAP-70 would be tyrosine phosphorylated in AB/ZAP-70-reconstituted cells after receptor engagement. Cell lines were rested overnight in the absence of exogenous IL-2 before stimulation of the TCR with a biotinylated anti-CD3 mAb (Leu4) followed by streptavidin. Immunoprecipitates were incubated in Jurkat T cells, as well as in the normal and reconstituted AB/ZAP-70 cells, but not in the AB cell line (Fig. 3). Within each cell line tested, the level of ZAP-70 protein immunoprecipitated before and after CD3 cross-linking was the same as that assessed by immunoblotting with an anti-ZAP-70 mAb. The level of ZAP-70 in the AB/ZAP-70b pool (equivalent to that in a normal HTLV-I T cell line), however, was approximately fivefold higher than in the AB/ZAP-70 pool (data not shown), accounting for the lower ZAP-70 kinase activity observed in AB/ZAP-70b, as compared with the normal and AB/ZAP-70, lines (Fig. 3). Interestingly, a protein with a molecular mass of ~140 kD, which coimmunoprecipitated only in the antibody, and developed with enhanced chemiluminescence to assess the phosphorylation status of ZAP-70. (B) The blot was stripped and re-probed with a ZAP-70-specific mAb to assess the level of immunoprecipitated ZAP-70.

**Figure 1.** Map of the GIZAPSvNa vector. Shown are positions of the 5' long terminal repeat (5' LTR), ZAP-70 cDNA, SV-40 promoter/enhancer, neomycin phosphotransferase (neo) gene, and 3' long terminal repeat (3' LTR).

**Figure 2.** Retroviral-mediated transduction of the wild-type ZAP-70 gene results in ZAP-70 expression and its phosphorylation upon CD3 aggregation. (A) ZAP-70 was immunoprecipitated using a polyclonal rabbit antibody from a normal PBL line (Normal), a ZAP-70-deficient PBL line (AB), and a ZAP-70-deficient PBL line reconstituted by retroviral-mediated transduction with a wild-type ZAP-70 gene (AB/ZAP-70). 10^6 cells were either unstimulated (−) or stimulated (+) with a biotinylated anti-CD3 mAb followed by streptavidin. Immunoprecipitated lysates were fractionated on a polyacrylamide gel, analyzed by immunoblotting with the 4G10 monoclonal anti-phosphotyrosine antibody, and developed with enhanced chemiluminescence to assess the phosphorylation status of ZAP-70. (B) The blot was stripped and re-probed with a ZAP-70-specific mAb to assess the level of immunoprecipitated ZAP-70.
The presence of ZAP-70, was also phosphorylated after TCR stimulation. Although the identity of this second protein is not known, its phosphorylation also increased upon TCR ligation in both normal and reconstituted cell lines (Fig. 3). We are presently analyzing whether the 140-kD protein is expressed as a consequence of HTLV-I transformation, and furthermore, whether it can be coimmunoprecipitated with antibodies directed against different ZAP-70 epitopes.

**Calcium Mobilization after TCR Stimulation Is Dependent on ZAP-70 Expression.** The increases observed in cytosolic calcium concentrations \([\text{Ca}^{2+}]_i\) after TCR aggregation is absent in ZAP-70–deficient T cells (1–3). Calcium flux is one of the proximal events induced upon TCR stimulation (10–12, 33–35). We therefore assessed whether changes in \([\text{Ca}^{2+}]_i\), would be observed in reconstituted AB/ZAP-70 cells. For calcium measurements, cells were loaded with the calcium-sensitive dye Indo-1 and stimulated with a biotinylated CD3 mAb followed by streptavidin. Changes in \([\text{Ca}^{2+}]_i\), were then monitored by flurometry. In contrast to AB cells, in which little or no \([\text{Ca}^{2+}]_i\), flux was noted, normal cells and three different pools of AB/ZAP-70–reconstituted cells (including AB/ZAP-70, and AB/ZAP-70b) had a sustained increase in \([\text{Ca}^{2+}]_i\), upon receptor cross-linking (Fig. 4 and data not shown). Equivalent loading of all cell lines with Indo-1 was affirmed in all experiments by demonstrating calcium flux after addition of calcium ionophore (ionomycin; data not shown).

**Discussion**

We have shown that retroviral-mediated transduction of the wild-type ZAP-70 cDNA into a CD4+ HTLV-I–transformed T cell line from a ZAP-70–deficient patient results

![Figure 3](image-url)  
*Figure 3.* In vitro kinase activity of ZAP-70 is stimulated by TCR aggregation in ZAP-70–reconstituted cells. Jurkat T cells, as well as PBL lines from a normal individual (Normal), patient AB, and two different pools of ZAP-70–transduced cells (AB/ZAP-70, and AB-ZAP-70), were assessed for autophosphorylation. After TCR aggregation (+), lysates from \(10^7\) cells were immunoprecipitated with a polyclonal ZAP-70–specific antibody, and an in vitro kinase assay was performed. The amount of ZAP-70 immunoprecipitated before and after stimulation was identical, as assessed by a-ZAP-70 immunoblotting (not shown).

![Figure 4](image-url)  
*Figure 4.* ZAP-70 is required for calcium mobilization after TCR stimulation. Cells from a ZAP-70–deficient PBL line (AB), a ZAP-70–reconstituted line (AB/ZAP-70), and a normal PBL line (Normal), were loaded with the calcium-sensitive dye Indo-1 and analyzed for increases in \([\text{Ca}^{2+}]_i\). Cells were stimulated with a biotinylated α-CD3 antibody (Leu4-B) followed by streptavidin (SA), as indicated. Changes in \([\text{Ca}^{2+}]_i\), were monitored by fluorometry as a measure of the ratio of emission at 405/485 nm (ordinate axis) using a Photon Technologies spectrofluorometer for the indicated time period (s).
ecessary to determine whether T cell polyclonality and diversity of the T cell repertoire is maintained after transduction with the G1ZAPsvNa retroviral vector.

Multiple cellular PTKs interact with the TCR and contribute to the signal transduction pathway, including the Src family PTKs Lck and Fyn, as well as the ZAP-70 and related Syk PTKs (10-12, 35-38). Increased levels of Syk were observed in both the HTLV-I-transformed thymocyte and peripheral T cell lines derived from the ZAP-70-deficient patient described in this report (reference 26, and Bacon, K., S. Smith, T. Jahn, T. Kadlecek, A. Weiss, K. Weinberg, and N. Taylor, unpublished observations). Syk appears to compensate for ZAP-70 only under specific cellular conditions; TCR-stimulated calcium flux was observed in the patient's IL-2-dependent thymocyte cell line (26), but not in the IL-2-dependent peripheral T cell line derived from the same patient (Fig. 4). Nevertheless, upon transition of the patient's peripheral T cell line to IL-2 independence with concurrent activation of the JAK/STAT kinase pathway, as described previously (39-41), Syk was sufficient to mediate a calcium response (Bacon, K., and N. Taylor, unpublished observations). Work is in progress to address the relative contributions of these two PTKs to TCR signaling in ZAP-70-reconstituted thymocytes and T cells.

Our experiments focused on the role of ZAP-70 in TCR signaling, but the phenotypes of ZAP-70-deficient patients and mice indicate that ZAP-70 also plays an important role in T cell development (1-3, 42). ZAP-70-deficient patients have normal or increased numbers of CD4+ cells with a paucity of CD8+ cells, whereas mice with a targeted deletion of the ZAP-70 gene express neither CD8 nor CD4 single positive T cells (42). Introduction of ZAP-70 into hematopoietic stem cells isolated from the ZAP-70-deficient mouse may provide insights into the biological effects of exogenous ZAP-70 expression. It will be important to determine the bases of the differences between ZAP-70-deficient patients and mice, however, since gene therapy protocols for ZAP-70-deficient SCID patients will have to target a progenitor of T lymphocytes that is able to achieve correction of T cell ontogeny. The present experiments demonstrating correction of signal transduction through the TCR in a ZAP-70-deficient T cell line lay the foundation for these preclinical investigations.

We thank R. Parkman for continuous support, M. Dao for helpful discussion, J. Cambier for valuable suggestions regarding calcium flux, C. Paradise and B. Sefton for generously providing reagents, and E. Otto and C. Fusco for the pG1XSvNa vector.

N. Taylor is the recipient of a Howard Hughes Medical Institute Postdoctoral Physician Grant. The DNAX Research Institute is supported by the Schering-Plough Corporation. This work was supported in part by National Institutes of Health grant AI-40581 (to Kenneth Weinberg).

Address correspondence to Naomi Taylor at her present address, Institut de Génétique Moléculaire de Montpellier, 1919 Route de Mende, 34033 Montpellier, Cedex 1, France.

Received for publication 28 June 1996 and in revised form 27 August 1996.

References

1. Arpala, E., M. Shahar, H. Dada, A. Cohen, and C.M. Roifman. 1994. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking ZAP kinase. Cell. 76: 947–958.
2. Elder, M.E., D. Lin, J. Clever, A.C. Chan, T.J. Hope, A. Weissand and T.G. Parslow. 1994. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science (Wash. DC). 264:1596–1599.
3. Chan, A.C., T. Kadlecek, M. Elder, A. Filipovich, J. Grey, M. Iwashima, T. Pardow, and A. Weiss. 1994. ZAP-70 protein tyrosine kinase deficiency in an autosomal recessive form of severe combined immunodeficiency. Science (Wash. DC). 264:1599–1601.
4. Chan, A.C., N.S.C. van Oers, A. Tran, L. Turka, C.L. Law, J.C. Ryan, E.A. Clark, and A. Weiss. 1994 Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J. Immunol. 152:4758–4766.
5. Chan, A., M. Iwashima, C. Turck, and A. Weiss. 1992. ZAP-70: a 70kD protein tyrosine kinase that associates with the TCR-ζ chain. Cell. 71:649–662.
6. Weiss, A. 1993. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 73: 209–212.
7. Reth, M. 1989. Antigen receptor tail clue [letter]. Nature (London). 338:383–384.
8. Samelson, L.E., and R.D. Klausner. 1992. Tyrosine kinases and tyrosine-based activation motifs. Current research on activation via the T cell antigen receptor. J. Biol. Chem. 267: 24913–24916.
9. Cambier, J.C. 1995. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL). ImmunoL Today. 16:110.
10. Perlmutter, R.M., S.D. Levin, M.W. Appleby, S.J. Andersand, and J. Alberola-Ila. 1993. Regulation of lymphocyte function by protein phosphorylation. Annu. Rev. Immunol. 11:451–499.
11. Isakov, N., R.L. Wange, and I.E. Samelson. 1999. The role of tyrosine kinases and phosphotyrosine-containing recognition motifs in regulation of the T cell-antigen receptor-mediated signal transduction pathway, J. Leukoc. Biol. 55:265–271.
12. Chan, A.C., D.M. Desai, and A. Weiss. 1994. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu. Rev. Immunol. 12:521–554.
13. Wang, R.L., A.-N.T. Kong, and L.E. Samelson. 1992. A tyrosine-phosphorylated 70-kDa protein binds a photoaffinity analogue of ATP and associates with both the zeta chain and CD3 components of the activated T cell antigen receptor. *J. Biol. Chem.* 267:11685–11688.

14. Iwashima, M., B.A. Irving, N.C.S. van Oers, A.C. Chan, and A. Weiss. 1994. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. *Science (Wash. DC)*, 263:1136–1139.

15. Romeo, C., M. Amiot, and B. Seed. 1992. Sequence requirements for induction of cytolyis by the T cell antigen/Fc receptor ζ chain. *Cell.* 68:889–897.

16. Strauss, D.B., and A. Weiss. 1993. The CD3 chains of the T cell antigen receptor associate with the ZAP-70 tyrosine kinase and are tyrosine phosphorylated after receptor stimulation. *J. Exp. Med.* 178:1523–1530.

17. Tamguchl, T., T. Kobayashi, J. Kondo, K. Takahashi, H. Nakamura, J. Suzuki, K. Naga, T. Yamada, S. Nakamura, and H. Yamamaki. 1991. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to polyclonal activaton. *J. Biol. Chem.* 266:15790–15796.

18. Hutchcroft, I.E., R.E. Geahlen, G.G. Deanin, and J.M. Oliver. 1992. FcERI-mediated tyrosine phosphorylation and activation of the 72-kDa protein tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. *Proc. Natl. Acad. Sci. USA.* 89:9107–9111.

19. Takata, M., H. Sabe, A. Hata, T. Inazu, Y. Homma, T. Nakata, H. Yamamura, and T. Kurusaki. 1994. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. *EMBO (Eur. Mol. Biol. Organ.)* J. 13:1341–1349.

20. Law, D.A., V.W.-F. Chan, S.K. Datta, and A.L. DeFranco. 1993. B cell antigen receptor motifs have redundant signals for lympophilastic growth including their receptor, Lyn and Ptk72, Lyn and Fyn. *Curr. Biol.* 3:645–657.

21. Gharzadeh, S., J.B. Bolten, and H.B. Fleit. 1995. Tyrosine phosphorylation and association of Syk with FcγRII in monocytic THP-1 cells. *Biochem.* J. 305:669–674.

22. Agarwal, A., P. Salem, and K.C. Robbins. 1993. Involvement of p72syk, a protein-tyrosine kinase, in FcγRII receptor signaling. *J. Biol. Chem.* 268:15900–15905.

23. Benhamou, M., N.J. Ryba, H. Kihara, H. Nishikata, and R.P. Siraganian. 1993. Protein-tyrosine kinase p72syk in high affinity IγE receptor signaling. Identification of a component of p72 and association with the receptor chain after receptor aggregation. *J. Biol. Chem.* 268:23318–23324.

24. Jouvin, M.H., M. Adamczewski, R. Numerof, O. Letourneur, A. Valles, and J.P. Kine. 1994. Differential control of the tyrosine kinases lyn and syk by the two signaling chains of the high affinity immunoglobulin E receptor. *J. Biol. Chem.* 269:5918–5925.

25. Kiener, P.A., B.M. Rankin, A.L. Burkhardt, G.L. Scheven, I.D. Gilliland, R.B. Rowley, J.P. Boland, and J.A. Ledbetter. 1993. Cross-linking of FcγRI receptor (FcγRI) and receptor II (FcγRII) on monocytes activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. *J. Biol. Chem.* 268:24442–24449.

26. Gelland, E.W., K. Weinberg, B.D. Mazer, T.A. Kadlec, and A. Weiss. 1995. Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes. *J. Exp. Med.* 182:1057–1065.

27. Kohn, D.B., H. Mitsuya, M. Ballow, J.E. Selegue, J. Barankiewicz, A. Cohen, E. Gelfand, W.F. Anderson, and R.M. Blaese. 1989. Establishment and characterization of adenosine deaminase-deficient human T cell lines. *J. Immunol.* 142:3971–3977.

28. Miller, A.D., and G.J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. *Biotechniques.* 7:980–990.

29. Nolta, J.A., and D.B. Kohn. 1990. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. *Hum. Gen. Ther.* 1:257–268.

30. Miller, A.D., J.V. Garcia, N. von Suhr, C.M. Lynch, C. Wilson, and M.V. Eiden. 1991. Construction and properties of retrovirus packaging cells based on Gibbon ape leukma virus. *J. Virol.* 65:2220–2224.

31. Taylor, N., L. Uribe, S. Smith, T. Jahn, D.B. Kohn, and W. Weimb. 1996. Correction of Interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the ζ gene. *Blood.* 87:3103–3107.

32. Couture, C., G. Baier, C. Oetken, S. Williams, D. Telford, A. Marie-Cardine, G. Baier-Bitterlich, S. Fischer, P. Burn, A. Altman, and T. Mustelin. 1994. Activation of p56lck by p72Syk through physical association and N-terminal tyrosine phosphorylation. *Mol. Cell. Biol.* 14:5249–5258.

33. Gelfand, E.W. 1990. Ion movement, activation and signaling of T and B lymphocytes. In *Ligands, Receptors and Signal Transduction in Regulation of Lymphocyte Function.* J. Cambier, editor. American Society for Microbiology, Washington, DC. 359–386.

34. Altman, A., T. Mustelin, and K.M. Coggleshall. 1990. T lymphocyte activation: a biological model of signal transduction. *Curr. Rev. Immunol.* 10:347–391.

35. Selkon, B.M., and J.A. Taddie. 1994. Role of tyrosine kinases in lymphocyte activation. *Current Opin. Immunol.* 6:372–379.

36. Couture, C., G. Baier, A. Altman, and T. Mustelin. 1994. p56lck independent activation and tyrosine phosphorylation of p72Syk by T-cell antigen receptor/CD3 stimulation. *Proc. Natl. Acad. Sci. USA.* 91:5301–5305.

37. Kung, G., J. Bu, T. Kurosaki, A.S. Shaw, and A.C. Chan. 1995. Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. *Immunity.* 2:485–492.

38. Kolans, W., C. Romeo, and B. Seed. 1993. T cell activation by clustered tyrosine kinases. *Cell.* 74:171–183.

39. Maeda, M., N. Arma, Y. Daitoku, M. Kashihara, H. Oka-moto, T. Uchiyama, K. Shirono, M. Matsuoka, T. Hattori, K. Tatsuki et al. 1987. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukaemia. *Blood.* 70:1407–1411.

40. Yssel, H., R. de WaalMalefyt, M.D. Duc Doden, L. Gazzolo, J.E. de Vries, and H. Spits. 1989. Human T leukaemia/lymphoma virus type I infection of a CD4+ proliferative/cytotoxic T cell line. *Nature (Lond.).* 342:889–912.